Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase II Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

The purpose of this study is to evaluate the safety and efficacy of tislelizumab and SX-682 in patients with resectable pancreatic adenocarcinoma.

NCT#: NCT05604560
Study ID: J2291
Trial Phase: Phase II

Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center, BeiGene, Syntrix Pharmaceuticals
Therapies Used in This Trial: Tislelizumab, SX-682

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Back to Trial Search